• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Cambridge Heart halts ischemia pilot, gears up for prospective trial

Cambridge Heart halts ischemia pilot, gears up for prospective trial

October 5, 2011 By MassDevice staff

Cambridge Heart

Cambridge Heart (OTC:CAMH) is halting a pilot study and gearing up for a prospective trial to test its MTWA heart-attack test for detecting ischemic events.

The Tewksbury, Mass.-based company’s Microvolt T-Wave Alternans test is currently approved in the U.S. for detecting the risk of heart attack, or arrhythmia, president and CEO Ali Haghighi-Mood told MassDevice. The new trial will investigate whether the test can also predict ischemic events involving restricted blood flow to the heart.

The new trial was prompted by evidence from the pilot study that the MTWA test can not only help predict ischemia but also identify underlying heart disease that other tests miss,
Haghighi-Mood explained.

Sign up to get our free newsletters delivered right to your inbox

"Our technology is capable of detecting ischemic events which were not detected by other standard modalities," he told us. "Last June, after we accumulated a number of these cases, we thought there was enough evidence to go and start understanding the phenomenon a little better and investigate how to formally start a trial to investigate this new application."

Discovering that evidence wasn’t completely unexpected,
Haghighi-Mood added.

"It was pleasant, but not a surprise. There have been data in the lab setting and animal setting that by inducing ischemia, basically clipping an artery, you could create alternans. The question was how relevant is it to a patient population that’s at risk for an ischemic event and how, in a clinical setting, this can be utilized," he said. "Data that we have today suggest that it can add to what the standard practice is today and uncover cases that have not been detected by other modalities."

The new trial is expected to begin in six to nine months, Haghighi-Mood said. If the new theory proves out, it could expand the patient pool from 10 to 12 million to roughly 40 million, according to a Cambridge Heart spokeswoman. That would be a boon for Cambridge Heart, which has traveled a rocky road lately.

In April, Cambridge Heart warned that it doesn’t have enough cash to stay afloat past the end of the year and registered for a stock offering worth more than $7.8 million. The company plans to sell nearly 30.2 million shares for 26 cents apiece, according to the filing. In June, Cambridge Heart landed a big win when a division of UnitedHealth Group, the largest health insurer in the U.S., made the test a covered benefit for its members.

Last year the Food & Drug Administration cleared an OEM version of the MTWA module. In September, CAMH officials said that it had begun shipping its integrated OEM MTWA module with a non-invasive diagnostic cardiac test designed to detect the risk of sudden heart attack, made by Bothell, Wash.-based Cardiac Science.

Haghighi-Mood said the acquisition of Cardiac Science by India’s Opto Circuits last year threw a temporary wrench into the deal.

"We launched the product in September last year. A few weeks later [Cardiac Science] was bought out," he told us. "The penetration and placement of the product was slower that what we expecteed. Effective in July, we launched a new marketing program. The premise of it is that the product will be included in every Q-Stress that Cardiac Science sells. The intention was to make upfor the lost time and get the program jump-started fast."

Filed Under: Diagnostics, News Well Tagged With: Cambridge Heart Inc., Clinical Trials

More recent news

  • Medtronic partners with IRCAD on Hugo, Affera surgical training
  • 23andMe co-founder wins bid to take back control of company
  • Neurent Medical opens new manufacturing facility in Ireland
  • Brain Navi wins FDA nod for neurosurgical robot
  • Adona Medical completes enrollment in first-in-human interatrial shunt trial

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy